公开(公告)号：US20200246420A1

公开(公告)日：2020-08-06

申请号：US16775113

申请日：2020-01-28

申请人： Rhode Island Council on Postsecondary Education ,  Yale University

发明人： Yana K. Reshetnyak ,  Oleg A. Andreev ,  Anna Moshnikova ,  Donald M. Engelman

IPC分类号： A61K38/16 ,  A61K38/20 ,  A61K38/19

摘要： The invention features methods and compositions for eliciting an anti-tumor response in a subject comprising administering to the subject a pHLIP® construct comprising an antibody recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound. The construct increases the amount of the antibody recruiting molecule on the surface of a diseased cell.

公开(公告)号：US07687079B2

公开(公告)日：2010-03-30

申请号：US10371666

申请日：2003-02-21

申请人： Leo E. Otterbein ,  Augustine M. K. Choi ,  Beverley A. Moore ,  Anthony J. Bauer

发明人： Leo E. Otterbein ,  Augustine M. K. Choi ,  Beverley A. Moore ,  Anthony J. Bauer

IPC分类号： A61K33/00 ,  A61P1/00

CPC分类号： A61K33/00

摘要： The present invention relates to a method of treating ileus in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

摘要翻译： 本发明涉及一种治疗患者肠梗阻的方法，其包括向患者施用包含一氧化碳的药物组合物。

公开(公告)号：US20240359138A1

公开(公告)日：2024-10-31

申请号：US18650511

申请日：2024-04-30

申请人： Yale University ,  B.G. Negev Technologies and Applications Ltd. ,  Colorado School of Mines

发明人： Jack Gilron ,  Menachem Elimelech ,  Tzahi Cath

IPC分类号： B01D61/58 ,  B01D61/02 ,  B01D61/42 ,  B01D61/46 ,  C02F1/44 ,  C02F1/469 ,  C02F103/06 ,  C02F103/08

CPC分类号： B01D61/58 ,  C02F1/441 ,  C02F1/4693 ,  B01D61/026 ,  B01D61/422 ,  B01D61/463 ,  B01D2311/04 ,  B01D2313/243 ,  B01D2317/022 ,  B01D2317/025 ,  B01D2317/04 ,  C02F2103/06 ,  C02F2103/08 ,  C02F2301/046 ,  C02F2301/08 ,  C02F2303/22

摘要： Described herein is a reverse osmosis system, comprising: a feed source input, a high pressure feed pump fluidly connected to the feed source input, a reverse osmosis (RO) cascade fluidly connected to the high pressure feed pump; wherein the RO cascade comprises at least one low salt rejection reverse osmosis (LSRRO) stage including a LSRRO membrane and a seawater reverse osmosis (SWRO) stage including a SWRO membrane fluidly connected to the at least one LSRRO stage.
Also described herein is a reverse osmosis method, comprising: providing the reverse osmosis system of claim 1, inputting a high salinity fluid into the feed source input, increasing the pressure of the high salinity fluid via the high pressure feed pump, performing reverse osmosis via the RO cascade, and collecting at least one of a concentrate and a permeate.

公开(公告)号：US12128105B2

公开(公告)日：2024-10-29

申请号：US18180686

申请日：2023-03-08

申请人： YALE UNIVERSITY

发明人： David Caianiello ,  Edward Deramon ,  David Spiegel

IPC分类号： A61K47/54

CPC分类号： A61K47/549 ,  A61K47/545

摘要： The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

公开(公告)号：US20240350433A1

公开(公告)日：2024-10-24

申请号：US18684563

申请日：2022-08-16

申请人： Yale University ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

发明人： John H. Krystal ,  Gihyun Yoon ,  Ismene L. Petrakis

IPC分类号： A61K31/135 ,  A61K31/485 ,  A61P25/24 ,  A61P25/32

CPC分类号： A61K31/135 ,  A61K31/485 ,  A61P25/24 ,  A61P25/32

摘要： The present application provides pharmaceutical compositions and methods for treating diseases or disorders. The pharmaceutical composition comprises N-methyl-D-aspartate receptor modulator and μ-opioid receptor modulator. The present application also discloses formulations, dosing and administration routes for the pharmaceutical composition. Diseases can be treated by the pharmaceutical composition are also described.

公开(公告)号：US20240342293A1

公开(公告)日：2024-10-17

申请号：US17768145

申请日：2020-10-09

申请人： YALE UNIVERSITY

发明人： David SPIEGEL ,  David CAIANIELLO ,  Emily BRANHAM

IPC分类号： A61K47/54 ,  A61K47/68

CPC分类号： A61K47/549 ,  A61K47/68

摘要： The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.

公开(公告)号：US20240335430A1

公开(公告)日：2024-10-10

申请号：US18749726

申请日：2024-06-21

申请人： YALE UNIVERSITY ,  United States Government as represented by the Department of Veterans Affairs

发明人： Chadi Abdallah ,  John Harrison Krystal ,  Ronald Duman ,  Gerard Sanacora

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K9/08 ,  A61K31/135 ,  A61K45/06 ,  A61P25/24

CPC分类号： A61K31/436 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/135 ,  A61K45/06 ,  A61P25/24

摘要： The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

公开(公告)号：US12091455B2

公开(公告)日：2024-09-17

申请号：US16969707

申请日：2019-02-14

申请人： YALE UNIVERSITY

发明人： Andrew Wang ,  Wenjun Liu ,  Aaron Ring

IPC分类号： C07K16/28 ,  A61K35/15 ,  A61K38/16

CPC分类号： C07K16/2803 ,  A61K35/15 ,  A61K38/16 ,  C07K2317/71

摘要： The present invention provides compositions and methods for reducing inflammation. In one aspect, the present invention provides a protein inhibitor comprising an ectodomain of at least one TREM or TREML protein. The invention also relates to inhibiting the interaction between a TREM or TREML protein and mitochondria released or derived from necroptotic cells; or between a TREM or TREML protein and cardiolipin.

公开(公告)号：US12090145B2

公开(公告)日：2024-09-17

申请号：US17269470

申请日：2019-08-20

申请人： YALE UNIVERSITY ,  The United States Government as represented by the Department of Veterans Affairs

发明人： Chadi Abdallah ,  John Krystal ,  Ronald Duman ,  Gerard Sanacora

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K9/08 ,  A61K31/135 ,  A61K45/06 ,  A61P25/24

CPC分类号： A61K31/436 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/135 ,  A61K45/06 ,  A61P25/24

摘要： The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

公开(公告)号：US20240298987A1

公开(公告)日：2024-09-12

申请号：US18573604

申请日：2022-06-22

申请人： Yale University ,  The United States Government as represented by the Department of Veterans Affairs

发明人： Mehran Sadeghi ,  Mani Salarian ,  Kiran Gona ,  Jakub Toczek

IPC分类号： A61B6/00 ,  A61B5/055 ,  A61B6/03 ,  A61B6/42 ,  A61K45/06 ,  A61K51/08 ,  C07K4/00

CPC分类号： A61B6/481 ,  A61B5/055 ,  A61B6/032 ,  A61B6/037 ,  A61B6/4241 ,  A61K45/06 ,  A61K51/088 ,  C07K4/00 ,  A61K2123/00

摘要： In one aspect, the present disclosure relates to an imaging agent comprising a detectable moiety covalently bound or coordinated to a “Moiety A” selected from a peptide, a chelator, or an organic compound comprising a leaving atom or a leaving group that can be substituted with a radioisotope. “Moiety A” is covalently bound to a flexible linker which is further covalently bound to a polypeptide of between 2 and 20 glycine-proline-hydroxyproline repeats. In certain embodiments, the detectable moiety comprises a radioisotope or metal. In another aspect, the disclosure relates to a method of using the imaging agents of the present disclosure to detect collagen turnover in a subject.